OTTAWA — For the second year running, fewer Canadians are dying of opioid overdoses, and for once the country’s health officials allowed themselves a careful kind of relief. In 2025, 5,630 people died of opioid toxicity, about 1,700 fewer than the year before, a fall of 23 per cent that builds on a 17 per cent decline the year before that, according to federal data.
The figures, released on Monday, are the clearest sign in years that the trajectory of Canada’s toxic drug crisis has bent. They are also, on their own terms, still grim. A 23 per cent drop leaves more than fifteen people dying every day, and the country’s chief public health officer, Dr Joss Reimer, was careful not to oversell it, telling reporters the toll was unacceptably high even as it falls, CBC News reported. Relief and alarm, in this crisis, are not opposites.
Health Minister Marjorie Michel made the same point in blunter language, warning there was no single fix behind the numbers and no guarantee they would hold. Officials credit two main forces for the decline: shifts in the illegal drug supply itself, which is volatile in ways that can cut deaths as easily as it once drove them up, and the far wider distribution and use of naloxone, the medication that reverses an opioid overdose if it reaches someone in time.
That second factor is the one within human control, and it is the reason the curve is bending. Naloxone kits now sit behind pharmacy counters, in supervised consumption sites, in the bags of outreach workers and increasingly in the homes of people who use drugs and the families who love them. None of it cures addiction. All of it buys the minutes between an overdose and a death, and at the scale Canada has reached, those minutes add up to thousands of people still alive.
The caution from officials is not false modesty. The progress is uneven across the country, with some provinces and some communities seeing little of the national improvement, and the supply that drove the gains down could just as easily turn lethal again. A drug market built on illicit fentanyl and its analogues does not follow public-health plans, and a single more-toxic batch can erase a quarter’s worth of progress in a region within weeks. The same unpredictability that helped this year is the thing that makes officials refuse to celebrate.
It also lands amid wider pressure. The crisis has always tracked hardship, deepening where work, housing and treatment are scarcest, and it sits alongside the broader economic strain running through parts of the country. The treatment and outreach systems doing the work are stretched, part of a pattern of public-health systems across North America asked to hold more ground with less.
What the data cannot yet tell anyone is why, exactly, the deaths are falling, and how much of it is durable. If the gains came mostly from a quieter drug supply, they are borrowed and can be taken back. If they came from naloxone and the slow build-out of treatment and harm reduction, they are earned and can be defended. The honest answer, the one officials gave on Monday, is that it is some of both, and that no one yet knows the mix.
So the number that improved is also a warning. Five thousand six hundred and thirty people died last year of something Canada knows how to prevent in the moment, if not yet how to end. The decline is real, and it is worth saying plainly that thousands of people who would have died did not. Whether next year’s figure keeps falling or snaps back is a question the toxic supply will answer at least as much as any policy, and that is precisely what the people who released these numbers are afraid of.
